Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-centre, Randomised, Double-blind, Multiple-dose, Placebo-controlled, Parallel-group Trial Investigating the Effects of Semaglutide on ß-cell Function in Subjects With Type 2 Diabetes

NCT02212067 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT02212067
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02212067 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-centre, Randomised, Double-blind, Multiple-dose, Placebo-controlled, Parallel-group Trial Investigating the Effects of Semaglutide on ß-cell Function in Subjects With Type 2 Diabetes
Lead sponsor
Novo Nordisk A/S
Phase
Phase 1
Overall status
Completed
Start date
August 11, 2014
Completion date
May 11, 2015
Enrollment
87 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes, diabetes mellitus, type 2